Table 2 Radiotherapy details, response and survival outcomes for HNSCC patients receiving radiotherapy with or without concomitant cetuximab
From: Cetuximab and anemia prevention in head and neck cancer patients undergoing radiotherapy
| Â | Â | All (n=171) | Cetuximab plus RT (n=85) | RT alone (n=86) | P value |
|---|---|---|---|---|---|
RT Setting (n (%)) | Adjuvant | 66 (38.6) | 27 (31.8) | 39 (45.3) | 0.095 |
| Â | Definitive | 105 (61.4) | 58 (68.2) | 47 (54.7) | |
RT dose category (n (%)) | 70-72 Gy | 101 (59.1) | 63 (74.1) | 38 (44.2) | <0.001 |
| Â | 61-66 Gy | 57 (33.3) | 13 (15.3) | 44 (51.2) | |
|  | ≤60 Gy | 13 (7.6) | 9 (10.6) | 4 (4.7) | |
Radiologic response (n (%)) | Complete response | 49 (39.8) | 18 (27.3) | 31 (54.4) | 0.013 |
| Â | Partial response | 41 (33.3) | 28 (42.4) | 13 (22.8) | |
| Â | Stable disease | 3 (2.4) | 1 (1.5) | 2 (3.5) | |
| Â | Progressive disease | 30 (24.4) | 19 (28.8) | 11 (19.3) | |
Mortality at last follow up (n (%)) | Â | 99 (57.9) | 59 (69.4) | 40 (46.5) | 0.004 |